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PAEDIATRIC KNOWLEDGE GAP
Children - “not small adults” 
Vulnerable population with developmental, physiological 
and psychological differences between age groups and from 
adults
Paediatric dosage regimens cannot be simply extrapolated 
from adult data
Children - “Therapeutic orphans” 
Majority of marketed medicines not studied in children or 
approved for paediatric use (only 1/3 of all EMA medicines 
authorised 1995-2005 are licensed in children)
Ethical. economic, logistical and technical barriers for CT
Risks: adverse effects (overdosing), inefficacy (underdosing), 
improper formulations, delay in access to innovative 
medicines






 Congenital abnormalities  
Diagnosis, prevention and treatment of 
these conditions have to be investigated 
in children
Safe / effective treatments for adults may 
be dangerous / ineffective for children
Effective treatment at early stage of the 
disease may be beneficial
APPROPRIATE PAEDIATRIC FORMULATIONS
Purpose of good paediatric formulations is to achieve safe and 
accurate dose administration, reduce the risk of medication 
errors, and enhance the compliance with medications.
Basic criteria for paediatric drug formulations:
• Sufficient bioavailability 
• Safe excipients
• Palatable and/or acceptable properties
• Acceptable dose uniformity 
• Easy and safe administration
• Socio-cultural acceptability
• Precise and clear product information
Breitkreutz J, Boos J.  Paediatric and geriatric drug 
delivery. Exp Opin Drug Deliv 2007; 4:37–45
Technical challenges, such as: diversity of children, accuracy of 
dosing with lower paediatric doses and volumes, inability to 
swallow solid dosage forms, taste masking in oral forms, 
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Review of effects of pharm technologic aspects (formulation and dosage form; route and 
frequency of administration; and packaging, administration device, and user instruction) on 
patient-related outcomes (clinical efficacy, side effects and tolerability, patient preference, 
patient acceptance, administration errors, and adherence).
-limited clinical evidence to support pharmaceutical development programmes (side 
effects/tolerability and administration errors with no attention) 
-Poor methodologic quality, need for proper instruments to measure methodological quality 
(RCT/double blinding not appropriate)
-.Agreement on taxonomy of technological aspects and patient-related outcomes
-Creation of global database with literature on the development of pediatric pharmaceuticals to 
promote research in the neglected areas.

OFF LABEL AND UNLICENSED USE
2010 EU survey on 20 EU and 2 non-EU countries:
45-60% of all medicines in children used outside MA
Discrepancies across individual countries in unapproved medicines use due to 
differences in data collection methods,  prescribing habits and medicines regulatory 
status (approved or not, in all or some subsets). 
Make approved products available in all Member States through the Mutual 
Recognition and Decentralised Proceduresaddress the general lack of paediatric 
labelling in the SPC , foster harmonisation of information on the product labels
Therapeutic classes most frequently used as off label and unlicensed 
medicines in the EU
Antiarrhythmics




Antidepressants (selective serotonin reuptake inhibitors, serotonin-
norepinephrine reuptakeinhibitors, tricyclic antidepressants).  
Antimicrobials (macrolides, beta lacatmtamines plus beta-lactamase 
inhibitors, carbapenems) 
Corticosteroids (dexamethasone)
DATA AVAILABILITY AND DISSEMINATION
 Paediatric medicines in the Netherlands 
http://www.kinderformularium.nl/search/index.php
 Patient information for unlicensed and off-label 
medicines specially prepared by pharmacists and 
doctors (www.medicinesforchildren.org.uk).
 BNFc, WHO Formulary
ACHIEVEMENTS SINCE THE PAEDIATRIC
REGULATION (1)
Long-term impact: strengthening infrastructure, 
setting norms and standards, building capacity for 
research and development of paediatric medicines, 
improved pharmaceutical quality of paediatric
medicines (formulations/pharmaceutical forms)
CT: 350 trials/year (stable), number of trials in all 
populations declined 2007-2011, transparency (Eudra
CT)
PIP:70% proposed development of paediatric indications 
vs. 30% in the past, BUT, 25% of all agreed PIPs
submitted exclusively for neonatology (highest need)
Therapeutic areas cover mostly diseases in adults 
(endocrinology/gynecology/fertility/metabolism, 
infectious diseases, oncology, cardiovascular diseases), 
not unmet/priority therapeutic paediatric needs 
(paediatric malignancies, pain, neonates).  
ACHIEVEMENTS SINCE THE PAEDIATRIC
REGULATION (2)
 EU FP7 provides funding for 15 projects and 2 
investigator-driven clinical trials for off patient 
medicines (75 mill. Euros).  
 Centralized authorizations for paediatric use 
obtained for 34 new medicines, 38 new paediatric 
indications as variations of 33 already authorized 
medicines , 4 centrally authorized products had 
either a new pharmaceutical form, or a new route 
of administration, or a new strength authorized 
for paediatric use.   
 Rewards obtained for 12 medicines:  
SPC extensions for 11 medicines, 1 PUMA 
exclusivity for the Midazolam paediatric 
oromucosal form).
MAJOR GAPS AND CONSIDERATIONS
RELATED TO EC REGULATION
 PIP coverage for paediatric developments: more profit oriented, not matching public health 
needs (adults therapeutic areas, older children groups preferred by industry)
 Priority needs list should not only be based on existing off label medicines use, but 
proactive approach based on real therapeutic advances and prioritising ;therapeutic areas 
of interest to children
 ADR of off patent medicines use in children: Healthcare professionals to help monitor the 
safety of medicines and report suspected adverse drug reactions.  
 New EU Pharmacovigilance Regulation to cover both marketed and unlicensed/off label 
medicines in children.
 1 PUMA granted, so PUMA not adequate incentive to the industry for off-patent drugs.  
This may be linked to reimbursement rules which may not recognize PUMA and may 
attach little values to old medicines even if they include a new age-appropriate 
formulation/form.
 Does PUMA granted product have therapeutic benefit over existing treatments?  
 Midazolam has only minor therapeutic advances according to the French National 
Authority for Health (Prescrire)
 6 months - SPC extensions example with Cozaar ( Losartan Potassium) oral suspension 
(MSD) in France
 Losartan not standard treatment for hypertension in children
 Suspension not ready to use, not labeled properly, poor quality packaging prone to 
dosing mistakes (diluting)
 Medicine not available in pharmacies/wholesales and not included in the French 
reimbursement list, expensive, paid out-of-pockett, so unavailable and unaffordable
 But, the manufacturer was given 6-month extension to its market exclusivity on 
Losartan in France, even for its non-paediatric indications
DISCUSSION
Much progress done in the development of age-appropriate 
paediatric formulations, especially for oral route of 
administration.
Many innovative paediatric formulations and devices but 
few are available on the market, due to high costs (patents) 
and (un)willingness for refunds by health insurance bodies.
 Areas for future developments and research:
 New routes of administration such as oral-transmusosal
(buccal strips), intra-nasal and trans-dermal (for neonates
mainly).
 Children's ability to swallow and their preferences need to
be investigated. This will direct future formulation
research towards (mini) tablets, chewable tablets, 
dispersible tablets or more oral liquids.
 More research into alternative safe excipients for children
such as natural polymers (e.g. cyclodextrin to mask taste of 
drugs, improve solubility or protect drugs/patient).
CONCLUSIONS
 Regulations introduced for structured research in 
children and improved labelling 
 Structured clinical research in children required 
to avoid harm
 Better data collection re: use of medicines and 
burden of diseases (chronic diseases) in the EU
 Pharmacovigilance and health system data to be 
used for efficacy and risks of off label medicine
 Data availability and dissemination
